Literature DB >> 21397040

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways.

Zubair Shah1, Colleen Pineda, Thomas Kampfrath, Andrei Maiseyeu, Zhekang Ying, Ira Racoma, Jeffrey Deiuliis, Xiaohua Xu, Qinghua Sun, Susan Moffatt-Bruce, Frederick Villamena, Sanjay Rajagopalan.   

Abstract

Evidence from both clinical and experimental studies indicates that Di-peptidyl peptidase-IV (DPP-4) inhibition may mediate favorable effects on the cardiovascular system. The objective of this study was to examine the acute effects of DPP-4 inhibition on vascular responses and to study the underlying mechanisms of alteration in tone. Aortic segments from C57BL/6 mice were treated with vasoconstrictors and exposed to various doses of alogliptin, a selective DPP-4 inhibitor. Vasodilator responses were evaluated using pathway specific antagonists to elucidate mechanisms of response. In parallel experiments, cultured human umbilical vein endothelial cells (HUVEC) were exposed to varying concentrations of alogliptin to evaluate the effects on candidate vasodilator pathways. Alogliptin relaxed phenylephrine and U46619 pre-constricted aortic segments in a dose dependent manner. Relaxation responses were not affected by the glucagon-like peptide-1 (GLP-1) receptor antagonist, exendin fragment 9-39 (88 ± 6 vs. 91 ± 2, p < 0.001). Vascular relaxation to alogliptin was significantly decreased by endothelial denudation, L-N(G)-monomethyl-arginine citrate (L-NMMA) and by the soluble guanylate cyclase inhibitor ODQ. DPP-4 inhibition induced relaxation was completely abolished by a combination of L-NMMA, charybdotoxin and apamin. Incubation of HUVECs with alogliptin resulted in eNOS and Akt phosphorylation (Ser(1177) and Ser(473) respectively) paralleled by a rapid increase in nitric oxide. Inhibition of Src kinase decreased eNOS and Akt phosphorylation, in contrast to a lack of any effect on insulin mediated activation of the eNOS-Akt, suggesting that alogliptin mediates vasodilation through Src kinase mediated effects on eNOS-Akt. DPP-4 inhibition by alogliptin mediates rapid vascular relaxation via GLP-1 independent, Src-Akt-eNOS mediated NO release and the activation of vascular potassium channels.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21397040      PMCID: PMC4845951          DOI: 10.1016/j.vph.2011.03.001

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  36 in total

1.  Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells.

Authors:  G Zeng; F H Nystrom; L V Ravichandran; L N Cong; M Kirby; H Mostowski; M J Quon
Journal:  Circulation       Date:  2000-04-04       Impact factor: 29.690

2.  Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

Authors:  Amal K Bose; Mihaela M Mocanu; Richard D Carr; Christian L Brand; Derek M Yellon
Journal:  Diabetes       Date:  2005-01       Impact factor: 9.461

3.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

4.  Direct measurement of nitric oxide generation from nitric oxide synthase.

Authors:  Y Xia; J L Zweier
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

Review 5.  Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  Joshua J Neumiller; Lindy Wood; R Keith Campbell
Journal:  Pharmacotherapy       Date:  2010-05       Impact factor: 4.705

6.  GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP.

Authors:  Brian D Green; Katharine V Hand; Janette E Dougan; Bronagh M McDonnell; Roslyn S Cassidy; David J Grieve
Journal:  Arch Biochem Biophys       Date:  2008-08-07       Impact factor: 4.013

7.  Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

Authors:  Paul Covington; Ronald Christopher; Michael Davenport; Penny Fleck; Qais A Mekki; Elisabeth R Wann; Aziz Karim
Journal:  Clin Ther       Date:  2008-03       Impact factor: 3.393

8.  Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.

Authors:  Yusuke Moritoh; Koji Takeuchi; Tomoko Asakawa; Osamu Kataoka; Hiroyuki Odaka
Journal:  Eur J Pharmacol       Date:  2008-04-10       Impact factor: 4.432

9.  Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema.

Authors:  James Brian Byrd; Ajai Shreevatsa; Pradeep Putlur; Denis Foretia; Laurie McAlexander; Tuhin Sinha; Mark D Does; Nancy J Brown
Journal:  J Allergy Clin Immunol       Date:  2007-05-25       Impact factor: 10.793

10.  Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.

Authors:  Meghan Sauvé; Kiwon Ban; M Abdul Momen; Yu-Qing Zhou; R Mark Henkelman; Mansoor Husain; Daniel J Drucker
Journal:  Diabetes       Date:  2010-01-22       Impact factor: 9.461

View more
  54 in total

Review 1.  Cardiovascular impact of drugs used in the treatment of diabetes.

Authors:  Chris R Triggle; Hong Ding
Journal:  Ther Adv Chronic Dis       Date:  2014-11       Impact factor: 5.091

2.  Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.

Authors:  F Vittone; A Liberman; D Vasic; R Ostertag; M Esser; D Walcher; A Ludwig; N Marx; M Burgmaier
Journal:  Diabetologia       Date:  2012-05-18       Impact factor: 10.122

Review 3.  GLP-1 Agonists and Blood Pressure: A Review of the Evidence.

Authors:  Aditya Goud; Jixin Zhong; Matthew Peters; Robert D Brook; Sanjay Rajagopalan
Journal:  Curr Hypertens Rep       Date:  2016-02       Impact factor: 5.369

4.  Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.

Authors:  Michael E Widlansky; Venkata K Puppala; Tisha M Suboc; Mobin Malik; Amberly Branum; Kara Signorelli; Jingli Wang; Rong Ying; Michael J Tanner; Sudhi Tyagi
Journal:  Vasc Med       Date:  2017-02-01       Impact factor: 3.239

Review 5.  New insights into insulin action and resistance in the vasculature.

Authors:  Camila Manrique; Guido Lastra; James R Sowers
Journal:  Ann N Y Acad Sci       Date:  2014-03-20       Impact factor: 5.691

6.  Linagliptin treatment improves cerebrovascular function and remodeling and restores reduced cerebral perfusion in Type 2 diabetes.

Authors:  Trevor Hardigan; Abdul Yasir; Mohammed Abdelsaid; Maha Coucha; Sally El-Shaffey; Weiguo Li; Maribeth H Johnson; Adviye Ergul
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-06-29       Impact factor: 3.619

Review 7.  Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes.

Authors:  Scott C Thomson; Volker Vallon
Journal:  Curr Diab Rep       Date:  2018-04-13       Impact factor: 4.810

8.  Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats.

Authors:  Annayya R Aroor; James R Sowers; Shawn B Bender; Ravi Nistala; Mona Garro; Irina Mugerfeld; Melvin R Hayden; Megan S Johnson; Muhammad Salam; Adam Whaley-Connell; Vincent G Demarco
Journal:  Endocrinology       Date:  2013-05-07       Impact factor: 4.736

9.  Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial.

Authors:  Christian Ott; Iris Kistner; Mirjam Keller; Stefanie Friedrich; Carsten Willam; Peter Bramlage; Roland E Schmieder
Journal:  Diabetologia       Date:  2016-09-01       Impact factor: 10.122

Review 10.  Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease.

Authors:  Ramiro A Sanchez; Hugo Sanabria; Cecilia de Los Santos; Agustin J Ramirez
Journal:  World J Diabetes       Date:  2015-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.